HSCARG downregulates NF-κB signaling by interacting with USP7 and inhibiting NEMO ubiquitination

T Li1,2, J Guan1,2, S Li3, X Zhang3 and X Zheng*1,2

Nuclear factor κB (NF-κB) signaling is a central pathway that participates in a variety of key processes, including immunity, inflammation, cell growth and differentiation. The activity of NF-κB is strictly regulated by a cluster of proteins, and modifications of these proteins either promote or suppress signal transduction at various steps. Here we demonstrated that HSCARG suppresses TNFα-stimulated NF-κB signaling under physiological conditions. We elucidated the detailed mechanism through which HSCARG inhibits NF-κB activation. HSCARG interacts with NEMO and suppresses polyubiquitination of NEMO by interacting with the deubiquitinase USP7. HSACRG attenuates its inhibitory effect on NEMO ubiquitination in USP7 knockdown cells, and inhibition of NEMO polyubiquitination by USP7 is impaired in HSCARG−/− cells as well. Moreover, we demonstrated that USP7 is a negative regulator of TNFα-stimulated NF-κB activity. Altogether, our data indicate that HSCARG and USP7 function in concert in inhibiting polyubiquitination of NEMO, thus inhibiting NF-κB activity.

Cell Death and Disease (2014) 5, e1229; doi:10.1038/cddis.2014.197; published online 15 May 2014

Subject Category: Immunity

Nuclear factor κB (NF-κB) is a critical regulator of multiple genes that control immunity, differentiation and other stress-induced responses.1–3 In resting cells, NF-κB is retarded in the cytoplasm by interacting with the inhibitor of κB (IκB) that blocks the nuclear localization signal of NF-κB. In the canonical NF-κB signaling pathway, stimuli such as tumor necrosis factor α (TNFα) recognition by the TNF receptor leads to activation of the inhibitor of IκB kinase (IKK). IKK then phosphorylates IκBα, which results in K48-linked polyubiquitination of IκBα followed by proteasome-dependent degradation.4–6 NF-κB dimers are then released and translocated into the nucleus, where they bind to specific DNA sequences and initiate transcription.7

The activity of NF-κB is strictly modulated at multiple levels by variant proteins, and protein modification by ubiquitin has a key regulatory function.8,9 In addition to targeting IκBα for degradation followed by NF-κB precursor processing, ubiquitin has a critical role in activating IKK in a proteasome-independent manner.10–13 Initially, it was found that IKK can be activated by ubiquitination without proteasomal degradation in vitro.14 Soon after, a series of E3 ligases, which are now known as TNF receptor associate factors (TRAFs), were identified as key regulators of IKK by forming K63-linked ubiquitin chains on targeted proteins.15–17 In the TNFα-activated NF-κB pathway, TRAF2/5 catalyzes K63-linked ubiquitination of receptor-interacting protein 1 (RIP1) and subsequently promotes the interaction between RIP1 and NEMO.18,19 The IKK complex is composed of three subunits: IKKα, IKKβ and the regulatory subunit NF-kappa-B essential modulator (NEMO, also known as IKKγ). NEMO has a ubiquitin-binding domain that binds to polyubiquitin chains to form a huge complex that facilitates the interaction between IKKβ and its kinase TGF-β-activated kinase 1.18,19 B-cell lymphoma/leukemia 10 and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) are also reported to activate NF-κB by inducing K63-linked ubiquitin conjugation to NEMO.20,21

Several strategies have been used by cells to downregulate NF-κB and prevent persistent activation of NF-κB. For example, dephosphorylation of IKKβ by protein phosphatase 1, 2A or 2Cβ decreases IKKβ activity.22–24 Deubiquitinases (DUBs) have been reported to suppress NF-κB activation by removing ubiquitin chains.25–27 Among them, A20 and cylindromatosis (CYLD) are the most studied DUBs that negatively regulate NF-κB activation. As a target gene of NF-κB, A20 terminates NF-κB signaling in a negative feedback loop. NF-κB is persistently activated by TNFα in A20-deficient cells, and mice lacking A20 die prematurely owing to severe inflammation and cachexia.28,29 CYLD is also an important negative regulator by preventing spontaneous activation of NF-κB. NF-κB is constitutively activated in the absence of CYLD.30,31

HSCARG (also named NmrA-like family domain containing protein 1) is a newly identified NF-κB suppressor. In our previous study, we found that HSCARG inhibits TNFα- and IL-1-activated NF-κB by interacting with IKKβ and
suppressing its phosphorylation, but the detailed molecular mechanism remain to be elucidated. In this study, we show that HSCARG interacts with NEMO and suppresses polyubiquitination of NEMO. Further investigation demonstrate that HSCARG and ubiquitin-specific protease 7 (USP7; HAUSP) function together to inhibit NEMO polyubiquitination, and USP7 suppresses TNFα-induced NF-κB activation. In summary, our study uncovers the suppressive mechanisms of HSCARG and USP7 in the TNFα-activated NF-κB signaling pathway.

**Results**

HSCARG suppresses TNFα-stimulated NF-κB signaling. Our previous study shows that HSCARG inhibits NF-κB activity. To further confirm the inhibition of NF-κB signaling by HSCARG under physiological conditions, the Cre/ioxP system was used to generate HSCARG−/− HCT116 cell line by inserting an extra sequence into the fourth exon and adding further stop codons to disrupt the translation of HSCARG. Knockout of HSCARG was confirmed by PCR (Supplementary Figure S1a) and western blotting analyses (Figure 1a, left panel). And then the NF-κB activity of HSCARG−/− cells was analyzed. Upon TNFα treatment, IκB degradation was faster in HSCARG−/− cells compared with that in wild-type HCT116 cells with normal HSCARG (Figure 1b, right panel). Knockout of HSCARG also retarded the de novo synthesis of IκB (Figure 1b). We generated a stable human embryo kidney (HEK) 293T cell line expressing HSCARG (Figure 1a, right panel) and examined both the endogenously and ectopically expressed HSCARG (Supplementary Figure S1b). We found that IκB was accumulated more in stable HSCARG cells under resting state than that in HEK 293T cells. Consistently, a much higher level of IκB was detected in stable HSCARG cells followed by TNFα treatment (Figure 1b, lower panel).

We also found that knockout of HSCARG affected the subcellular translocation of NF-κB. HSCARG−/− cells were treated with TNFα, and then localization of p65 in the nucleus and cytoplasm was examined by western blotting analysis. The result showed that a higher amount of p65 translocated from the cytoplasm into the nucleus in HSCARG−/− cells when compared with that in control cells (Figure 1c). The observations that TNFα-stimulated NF-κB activity increased significantly in HSCARG−/− cells demonstrate that HSCARG is a strong inhibitor in the NF-κB signaling pathway under physiological conditions.

HSCARG interacts with NEMO and inhibits its polyubiquitination. Identification of HSCARG as a strong inhibitor of NF-κB activity encouraged us to elucidate the detailed molecular mechanism. Both ectopic and endogenous co-immunoprecipitation (co-IP) analysis showed that HSCARG interacted with NEMO (Figure 2a, left and middle panels, Supplementary Figure S3a), and TNFα treatment promoted this interaction (Figure 2a, right panel). Because NEMO can be modified by K63-linked ubiquitin chains, which is a key event for its interaction with upper intermediates and signal transduction, we next investigated whether HSCARG affected NEMO polyubiquitination. His-ubiquitin pull-down analysis showed that, in HEK 293T cells, endogenous NEMO was strongly detected with conjugated ubiquitin chains (Figure 2b, Supplementary Figure S3b). When HSCARG was over-expressed, polyubiquitin-conjugated NEMO decreased obviously, indicating that HSCARG strongly suppresses polyubiquitination of NEMO (Figure 2b). To further confirm the physiological function of HSCARG, we analyzed the variation of endogenous ubiquitinated NEMO after TNFα treatment. The results showed that TNFα treatment promoted NEMO ubiquitination, which was suppressed by ectopic expression of HSCARG (Figure 2c, Supplementary Figure S3b). On the contrary, knockout of HSCARG obviously increased the level of endogenous NEMO ubiquitination (Figure 2d, Supplementary Figure S3b). Altogether, these results indicate that HSCARG interacts with the regulatory subunit NEMO of the IKK complex and inhibits NEMO ubiquitin modification.

HSCARG interacts with USP7 and inhibition of NEMO polyubiquitination by HSCARG relies on the deubiquitination activity of USP7. As described above, HSCARG interacted with NEMO and inhibited its polyubiquitination. Because protein polyubiquitination has a key role in activation, regulation and termination of the NF-κB pathway, and HSCARG is not a DUB, it is conceivable that HSCARG suppresses NF-κB by interacting with some DUBs that can regulate polyubiquitin conjugation of NEMO. Several DUBs, including A20, CYLD and USP7, have been reported to downregulate NF-κB. Co-IP assays were thus carried out to examine the interactions between these enzymes and HSCARG, and the results showed that HSCARG interacts weakly with A20 or CYLD but strongly interacts with USP7 (Figure 3a, Supplementary Figure S3c). Furthermore, the interaction between endogenous HSCARG and USP7 in cells treated with or without TNFα was investigated by co-IP assay. As expected, endogenous USP7 interacted with HSCARG, which was promoted by TNFα treatment (Figure 3b, Supplementary Figure S3d). Next, we examined whether knockdown of NEMO by siRNA affects the interaction between HSCARG and USP7. The result showed that knockdown of NEMO suppressed the binding between HSCARG and USP7, indicating an essential role of NEMO in regulating the interaction between HSCARG and USP7 (Figure 3c, Supplementary Figure S3e). We next investigated whether inhibition of NEMO polyubiquitination by HSCARG depended on USP7. In HEK 293T cells with depleted USP7 by shRNA, inhibition of NEMO polyubiquitination by HSCARG was attenuated obviously (Figure 3d, Supplementary Figure S3f). These results indicate that inhibition of NEMO ubiquitination by HSCARG relies on the deubiquitination activity of USP7.

USP7 interacts with NEMO and inhibits its polyubiquitination, and HSCARG is critical for the deubiquitination activity of USP7. We further examined whether USP7 interacted with NEMO and affected the level of NEMO polyubiquitination. USP7 and NEMO were co-transfected into HEK 293T cells, and co-IP experiment was carried out to analyze the interaction between these two proteins. We found that USP7 was immunoprecipitated with NEMO (Figure 4a, Supplementary Figure S3g). Moreover, an expression vector encoding Flag-NEMO was co-transfected with USP7 and HA-HSCARG into HEK293T cells or HSCARG−/− HEK293T cells, and then the interaction among these three proteins was...
examined by co-IP analysis. The results showed that USP7, HSCARG and NEMO were immunoprecipitated together (Figure 4b left panel, Supplementary Figure S3h), and knockout of HSCARG impaired the binding between NEMO and USP7 (Figure 4b middle panel, Supplementary Figure S3h), indicating that these three proteins form a complex. This was confirmed by the endogenous co-IP experiments as shown in Figure 4b (right panel, Supplementary Figure S3h), in which TNFα treatment promoted the complex formation. To determine whether USP7 deubiquitinated NEMO polyubiquitination, we examined and compared the levels of NEMO polyubiquitination in HEK 293T cells with or without ectopic USP7. As expected, the results of ubiquitin conjugation assays showed that overexpression of USP7 strongly inhibited polyubiquitination of NEMO (Figure 4c, Supplementary Figure S3i).

The aforementioned data demonstrated that both HSCARG and USP7 inhibit NEMO polyubiquitination, and suppression of NEMO polyubiquitination by HSCARG is dependent on USP7. Next, we investigated whether HSCARG had a critical role in regulating the deubiquitination activity of USP7. The deubiquitination activity of USP7 was impaired in cells when HSCARG was knocked out (Figure 4c). Co-IP assay further confirmed that overexpression of USP7 had a weak effect on NEMO ubiquitination in HSCARG−/− cells (Figure 4d). All these data indicate that HSCARG and USP7 function in concert in inhibiting NEMO polyubiquitination, and HSCARG is important for the deubiquitination activity of USP7.

USP7 inhibits TNFα-induced NF-κB activation. Inhibition of NEMO polyubiquitination by USP7 suggested that USP7 probably inhibited cytokine-induced NF-κB activation. We hence examined the effects of USP7 on IκBα phosphorylation, p65 cytoplasm–nuclear translocation and NF-κB transcriptional activity in TNFα-treated cells (Figure 5). Compared with control cells, knockout of USP7 in HCT116 cells stimulated the degradation of IκBα, while overexpression of USP7 in 293T cells completely abolished the degradation of IκBα. These observations were consistent with the changes of IκBα phosphorylation (Figure 5a). We also found that overexpression of USP7 strongly suppressed translocation of p65 from the cytoplasm into the nucleus (Figure 5b). An NF-κB luciferase reporter assay was carried out to analyze the effect of USP7 on TNFα-induced NF-κB transcriptional activity in a dose-dependent manner (Figure 5c). We further confirmed the regulatory role of HSCARG on USP7 activity by examining the influence of USP7 on IκBα degradation in HSCARG−/− cells. The results showed that knockout of HSCARG attenuated the blocking effect of USP7 and promoted the degradation of IκBα (Figure 5d). IL-8 is a reported target of NF-κB.33 We also assessed the effect of USP7 on TNFα-induced IL-8 activation, and the result showed that USP7 strongly suppressed the activation of IL-8.

**Figure 1** HSCARG is a suppressor of NF-κB signaling. (a) Immunoblot analysis of HSCARG expression in HSCARG−/− cells (left panel) and HSCARG-stable cells (right panel). (b) Knockout of HSCARG promotes degradation of IκBα (upper panel) while stable expression of HSCARG inhibits degradation of IκBα (lower panel). Cells were treated with TNFα (10 ng/ml) for the indicated time, and then immunoblotting was performed using antibodies against IκBα. Actin was used as a loading control. (c) Knockout of HSCARG results in nuclear accumulation of p65 stimulated by TNFα. Cells were treated with TNFα (10 ng/ml) for the indicated time, and then nuclear and cytoplasmic extracts were prepared. The distribution of endogenously expressed p65 was analyzed by immunoblotting using an anti-p65 antibody. Lamin B and α-tubulin were used as nuclear and cytoplasmic controls, respectively.
Taken together, these data indicate that USP7 inhibits TNFα-induced NF-κB activation and functions together with HSCARG in negatively regulating TNFα-stimulated NF-κB signaling pathway.

Discussion

The NF-κB signaling pathway responds to various stimuli, such as cytokines, and oxidative and genotoxic stresses, which results in transcription of hundreds of genes. Both activation and termination of NF-κB activity are strictly modulated at certain steps. In comparison to the many reported NF-κB activators, fewer suppressors have been identified. HSCARG is a newly identified NF-κB inhibitor. Here we elucidated the detailed mechanism in which HSCARG inhibits NF-κB activity. HSCARG interacts with USP7 and inhibits the polyubiquitination of NEMO, which decreases proteasomal degradation of IκBα and further inhibits NF-κB activity (Figure 6). We also characterized the inhibitory function of USP7 in the TNFα-activated NF-κB signal pathway.

Protein ubiquitination has important functions in positive and negative regulation of the NF-κB signaling pathway. Polyubiquitination of NEMO is essential for IKK activation that is required for activation of NF-κB. In addition to K63-linked ubiquitin conjugation, NEMO is conjugated with linear ubiquitin chains by the linear ubiquitin chain assembly complex, which is also involved in TNFα-induced NF-κB activation. In this study, we demonstrated the suppression role of HSCARG on the ubiquitin conjugation of NEMO, indicating that HSCARG negatively regulates NF-κB signaling via inhibition of NEMO polyubiquitination. To further elucidate the detailed molecular mechanism in which HSCARG inhibits NEMO ubiquitination, we examined the interaction between HSCARG and several DUBs, including A20, CYLD and USP7, to evaluate whether HSCARG suppresses NEMO ubiquitination by interacting with some DUBs. We found that HSCARG interacts with USP7, and inhibition of NEMO polyubiquitination and NF-κB activity by HSCARG relies on the deubiquitination activity of USP7.

In our previous study, we demonstrated that HSCARG interacts with IKKβ and suppresses its phosphorylation by promoting the interaction between PP2A and IKKβ, which provided one of the possible mechanisms to explain how HSCARG inhibits IKKβ phosphorylation and NF-κB activity. To further investigate which protein was the direct interaction partner of HSCARG, we carried out in vitro pull-down assays between HSCARG and NEMO or IKKβ. Our result showed that NEMO, but not IKKβ, was the direct interaction partner of HSCARG (Supplementary Figure S2a). Next, we examined whether IKKβ affected NEMO-HSCARG interaction. The result showed that knockdown of IKKβ by siRNA did not
affect the binding between HSCARG and NEMO (Supplementary Figure S2b). These results indicate that HSCARG is likely to directly interact with NEMO and inhibit NEMO ubiquitination, which further affect IKKβ phosphorylation. With regard to the observation that HSCARG regulates NF-κB activity by affecting the degradation of RelA, it occurs in the nucleus, indicating a spatiotemporal regulatory effect of HSCARG on NF-κB activation. All together, these data indicate that HSCARG regulates NF-κB pathway through different mechanisms.

USP7 has been found to participate in virus-mediated ubiquitination pathways. It has been reported that ICP0, a herpes simplex virus (HSV)-encoded protein, downregulates NEMO ubiquitination by interacting with USP7, and subsequently terminates Toll-like receptor-mediated NF-κB activation induced by HSV infection. USP7 also deubiquitinates RNA transcriptional activator-associated ubiquitin ligase and prevents it from self-deubiquitination-mediated degradation. Recently, USP7 was reported to regulate NF-κB transcription activity in the nucleus. Here we demonstrated the suppressive role of USP7 in the TNFα-activated NF-κB signaling pathway. Our results indicate that, in addition to virus-stimulated immunity, USP7 also regulates cytokine-triggered inflammatory reactions. Our findings present an important downregulatory mechanism of NF-κB in addition to A20 and CYLD.

Our study also uncovered the critical role of HSCARG in regulating USP7 activity. Inhibition of NEMO ubiquitination by HSCARG is dependent on USP7 (Figure 3c), and the deconjugation ability of USP7 is limited when HSCARG is knocked out or knocked down (Figures 4c and d). We demonstrated that HSCARG and USP7 function cooperatively in suppression of NEMO ubiquitination. These observations indicate that both HSCARG and USP7 are essential in downregulation of NEMO ubiquitination. USP7 functions as a negative regulator of IKK activation by deubiquitination, and HSCARG is a key adaptor protein that functions in a coordinate manner.

It has been reported that certain viruses inhibit NF-κB activity by recruitment of DUBs to escape destruction by host cells. Because HSCARG inhibits NF-κB activity by interacting with USP7, we hypothesize that HSCARG may function in virus-induced immunoreactions, which needs further investigation. In summary, we demonstrate that HSCARG interacts with NEMO and suppresses polyubiquitination of NEMO by interacting with USP7, which further elucidate the detailed mechanism of how HSCARG inhibits NF-κB activity.
As overactivation of NF-κB leads to persistent inflammation and immunoreactions that may cause damage and tumorigenesis, the important role of HSCARG in balancing NF-κB activation suggests that it is a potential target for treating inflammatory diseases and cancer.

**Materials and Methods**

**Antibodies and plasmids.** Mouse anti-Myc (M47-3), anti-α-tubulin M175-3, anti-His (D291-3) and rabbit anti-β-actin were purchased from MBL (Nagoya, Japan); mouse anti-Flag (F3165) and anti-HA (H9658) from Sigma (St. Louis, MO, USA); and rabbit anti-IκBα (No.9242), anti-p-IκBα (No.2859), anti-p65 (No.4764), anti-USP7 (No.4833) and anti-NEMO (No.2685) from Cell Signaling Technology (Beverly, MA, USA). Recombinant TNFα and IL-1 were from PeproTech (Rocky Hill, NJ, USA). HSCARG was cloned into expression vectors pRK-HA, pRK-Flag and pcDNA-Myc-His, respectively, and verified by DNA sequencing. NEMO were cloned into pRK-HA or pRK-Flag expression vector. The shRNA plasmids were constructed by Shanghai Genechem Corporation (Shanghai, China). siRNA of NEMO (sc-29363) and IKKβ (sc-35644) were from Santa Cruz (Dallas, TX, USA). The sequences of the sense strand of USP7 shRNA was 5'-ACCCUUGGA CAAUACCU-3' and 5'-AGUCGUUCAGUCGUCUAU-3'.

**Cell culture and plasmid transfection.** HEK 293T and HCT116 cells were cultured in Iscove’s Modified Dulbecco's Medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal calf serum (HyClone, Logan, UT, USA) at 37 °C in 5% CO2. Plasmids were transfected using MegaTran 1.0 transfection reagent following the manufacturer’s instructions (Origene, Rockville, MD, USA).

**Construction of HSCARG stable HEK 293T cell line.** Recombinant retrovirus expressing Flag-HA-tagged HSCARG and interleukin-2 receptor (IL-2R) α was constructed and transduced into HEK 293T cells. The positive cells expressing ectopic HSCARG were sorted by anti-IL-2R monoclonal antibody (13-0259, eBioscience, San Diego, CA, USA) conjugated with magnetic beads (MACS), and the expression of HSCARG was further confirmed by western blotting using anti-Flag/HA antibodies.

**Co-IP assay.** Cells were harvested and lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, pH 7.4, 1 μg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin and 1 μg/ml pepstatin). The whole-cell lysate was preincubated by incubating with 70 μl protein G sepharose beads (GE Healthcare, Milwaukee, WI, USA) at 4 °C for 1 h. Antibodies (5 μg) or control IgG were added to 1 ml preincubated cell lysate for each reaction, and the sample was rotated overnight at 4 °C. Then, protein G sepharose beads were added and incubated for another 3 h. The sepharose beads were pelleted by centrifugation and washed three times with RIPA buffer. The pellets were boiled in sample buffer and analyzed by immunoblotting.
centrifugation at 800 × g for 5 min and then washed three times with RIPA buffer. Precipitated proteins were fractionated by 12% SDS-PAGE and then transferred onto a nitrocellulose membrane (GE Healthcare). Membranes were probed with the indicated primary antibody for 2 h at room temperature, followed by the secondary antibody, and then detected using an Odyssey Infrared Imaging System and the software Odyssey V3.0 (LI-COR Biosciences, Lincoln, NE, USA).

His-ubiquitin pull-down assay. Cells were first transfected with a His-ubiquitin plasmid and other plasmids as indicated. At 48 h posttransfection, cells were harvested and washed once with phosphate-buffered saline. For each reaction (1 × 10^6 cells), 6 ml cell lysis buffer (6 M guanidinium chloride, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, pH 8.0) was added; followed by incubation for 30 min at room temperature. N2 + --nitrilotriacetic-acid agarose beads (75 μl) were added and incubated for another 4 h. The beads were collected by centrifugation at 2000 × g for 5 min and then sequentially washed with cell lysis buffers, buffer A (8 M urea, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, pH 8.0), buffer B (8 M urea, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, pH 6.3) and buffer C (8 M urea, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, 0.1% Triton X-100, pH 8.0). Finally, the beads were mixed with 50 μl elution buffer containing 0.2 M imidazole, 5% SDS, 0.15 M Tris-HCl, 10% glycerol, pH 6.7 and boiled in SDS loading buffer. Fifteen microliters of each sample was loaded onto a 12% SDS-PAGE gel and analyzed by immunoblotting.

Luciferase reporter assay. HEK 293T cells were cultured in 24-well plates at 2 × 10^4 cells per well. After 24 h, cells were transfected with a 1-μg plasmid mixture. pRL-CMV (5 ng) was cotransfected as a control. After 16 h, cells were treated with TNFα (10 ng/ml) for 6 h, and then luciferase activity was assessed with a dual luciferase reporter assay kit according to the manufacturer’s instructions (Promega, Madison, WI, USA). Each assay was performed in triplicate for at least three independent experiments.
Nuclear and cytoplasmic extract assay. HEK 293T or HCT116 cells were cultured in 6-cm dishes and harvested at 48 h. Nuclear and cytoplasmic extracts were prepared using Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Waltham, MA, USA). Extracts were then fractioned by SDS-PAGE and analyzed by immunoblotting. LaminB and α-tubulin were used as nuclear and cytoplasmic loading controls, respectively.

Quantitative real-time PCR. RNAs were extracted using TRIzon reagent (CWBIO, Beijing, China) according to the manufacturer’s instructions. The cDNAs were synthesized with FastQuant RT Kit (TIANGEN, Beijing, China), and qPCR were performed in Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) using the SYBR Green Supermix (Bio-Rad). The primers used are as follows:

- **GAPDH forward primer**: 5'-AACGGATTTGGTCGTATTGGG-3';
- **GAPDH reverse primer**: 5'-TCGCTCCTGGAAGATGGTGAT-3';
- **IL-8 forward primer**: 5'-CGGAAGGAACCATCTCACTGTG-3'; and
- **IL-8 reverse primer**: 5'-AGAAATCAGGAAGGCTGCCAAG-3'.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. We sincerely thank Dr. Bert Vogelstein at Ludwig Center at Johns Hopkins for providing us USP7 knockout cell line. We thank Dr. Goedele Maertens at Cancer Research UK, Dr. Danying Chen at Peking University and Dr. Zhijian Chen at University of Texas Southwestern Medical Center for providing plasmids USP7 and NEMO and ubiquitin. This work was supported by grants from the National Science Foundation of China 30330020, the National High Technology and Development Program of China 973 programs (No. 2010CB911800), Doctoral Fund of Ministry of Education of China (20130001130003) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) (Project No.CRP/CHN09-01).

References
1. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008; 132: 344–362.
2. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–288.
3. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225–260.
4. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-κB controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993; 259: 1912–1915.
5. Cheri G, Guddel DV, TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634–1635.
6. Karin M. How NF-κB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867–6874.
7. Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33–40.
8. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49–52.
21. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M et al.

24. Li HY, Liu H, Wang CH, Zhang JY, Man JH, Gao YF

22. Prajapati S, Verma U, Yamamoto Y, Kwak YT, Gaynor RB. Protein phosphatase 2Cbeta

18. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires

19. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked

16. Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu Z. The distinct roles of TRAF2 and RIP

14. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel

13. Windheim M, Stafford M, Peggie M, Cohen P. Interleukin-1 (IL-1) induces the Lys63-linked

12. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Cell Death

26. Reyes-Turcu FE, Wilkinson KD. Polyubiquitin binding and disassembly by deubiquitinating

27. Harhaj EW, Dixit VM. Regulation of NF-kappaB by deubiquitinases. Immunol Rev

28. Lee EG, Boone DL, Chai S, Libby SL, Chen M, Lodolce JP et al. Failure to regulate TNF-induced

25. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-kappaB signaling. Cell Res

29. Reverecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30: 383–391.

30. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M et al. Regulation of early wave of
germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007; 13: 705–716.

31. Zhang J, Stirling B, Temmerson ST, Ma CA, Fuss UJ, Derr JH et al. Impaired regulation of

32. Lian M, Zheng X. HSCARG inhibits activation of NF-kappaB by

33. Wan F, Anderson DE, Bartmiz RA, Snow A, Bidere N, Zheng L et al. Ribosomal protein S3:

34. Tang ED, Wang CY, Xiong Y, Guan KL. A role for NF-kappaB essential modifier/IkappaB

35. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K et al. Involvement of

36. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K et al. Implication of linear polyubiquitinylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009; 11: 123–132.

37. Verhelst K, Verstrepen L, Carpenter I, Beyaert R. Linear ubiquitination in NF-kappaB

38. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i

39. Van der Heyden K, Chisari F. Involvement of linear polyubiquitinylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009; 11: 123–132.

40. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i

41. Colleran A, Collins PE, O’Carrol C, Ahmed A, Mao X, McManus B et al. Deubiquitination of

42. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i

43. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i

44. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i

45. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i